Exocrine Pancreatic Insufficiency Treatment Market size was USD 2.8 billion in 2024 and is estimated to reach USD 5.7 billion by the end of 2037, expanding at a CAGR of 5.9% during the forecast period, i.e., 2025-2037. In 2025, the industry size of exocrine pancreatic insufficiency treatment is evaluated at USD 2.9 billion.
The increasing incidence of conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic cancer, which are leading causes of exocrine pancreatic insufficiency (EPI) are anticipated to augment the demand for EPI therapeutic approaches in the coming years. The Cystic Fibrosis Foundation study across 94 countries reveals that there are over 105,000 individuals living with cystic fibrosis. Furthermore, the National Center for Biotechnology Information (NCBI) reveals that chronic pancreatitis leads to 30% to 90% of EPI prevalence rates. The long disease duration and alcoholic etiology are prime factors associated with exocrine pancreatic insufficiency occurrence. The older population who are more susceptible to conditions such as chronic pancreatitis and pancreatic cancer are also the prime contributors to EPI drug sales.
The expansion of immunology and gut health product offerings is aiding the market players in uplifting their revenue shares. For instance, in October 2024, AbbVie, Inc. revealed its third quarter 2024 financial results. As per the report, the company totaled global net revenues of 14.46 billion with a rise of 3.8% on a reported basis and 4.9% on an operational basis. The worldwide immunology portfolio's net revenues were evaluated at USD 7.04 billion an increase of 4.8% on an operation basis and 3.9% on a reported basis. Furthermore, the R&D expense on the generally accepted accounting principle (GAAP) basis was 14.7% of net revenues.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.9% |
|
Base Year Market Size (2024) |
USD 2.8 billion |
|
Forecast Year Market Size (2037) |
USD 5.7 billion |
|
Regional Scope |
|
Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT))
By 2037, pancreatic enzyme replacement therapy (PERT) segment is estimated to hold more than 89.4% exocrine pancreatic insufficiency treatment market share. The rising prevalence of chronic pancreatic diseases such as cystic fibrosis and pancreatic cancer are prime factors driving the adoption of pancreatic enzyme replacement therapies (PERT). For instance, in August 2024, Exelixis, Inc. announced that it received approval from the U.S. Food and Drug Administration for its supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX). This drug is effective for the treatment of well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and extra-pancreatic NET (epNET) in adults. Continuous improvements in the formulations of pancreatic enzymes are further enhancing PERT’s effectiveness. The development of pancreatic micro-tablets and capsules is making the therapy more efficient, leading to better patient outcomes and high demand.
Symptom (Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Others)
In exocrine pancreatic insufficiency treatment market, diarrhea segment is expected to hold more than 28% revenue share by 2037. Diarrhea is the prime symptom leading to exocrine pancreatic insufficiency issues. The World Health Organization (WHO) report reveals that diarrhea is the leading cause of malnutrition among children and around 1.7 billion cases of diarrheal disease are diagnosed each year, across the world. Pancreatic enzyme replacement therapy effectively improves digestion, especially of fats by providing exogenous enzymes, leading to mitigation of occurrence and severity of diarrhea.
Our in-depth analysis of the global exocrine pancreatic insufficiency treatment market includes the following segments:
|
Treatment |
|
|
Drug Type |
|
|
Symptom |
|
|
Distribution Channel |
|
North America Market Forecast
North America exocrine pancreatic insufficiency treatment market is expected to capture revenue share of over 56.1% by 2037. The presence of research organizations, the existence of advanced healthcare infrastructure and pharma companies, and increasing public investments in research and development activities are collectively contributing to the overall market growth. Both the U.S. and Canada are foreseen to offer lucrative opportunities to exocrine pancreatic insufficiency drug manufacturers owing to the rising prevalence of pancreatic conditions.
In the U.S., according to the American Cancer Society, around 66,440 individuals were diagnosed with pancreatic cancer in 2024. Furthermore, pancreatic cancer accounts for 3.0% of the overall cancer types. Such rising cancer incidence rates are fueling the demand for exocrine pancreatic insufficiency therapeutic solutions. The increasing awareness programs of gastrointestinal health are leading to early diagnosis and treatment of exocrine pancreatic insufficiency.
In Canada, the government’s supportive role in advancing its healthcare system is leading to increasing access to essential treatments including exocrine pancreatic insufficiency for a larger population. The increasing funding for research and development activities is also anticipated to drive the exocrine pancreatic insufficiency treatment market growth in the country. For instance, the Canadian Institutes of Health Research (CHIR) contributed around USD 352,57o to a project titled - Pancreatic Enzyme Replacement Therapy to Improve Quality of Life in Patients Undergoing Pancreatoduodenectomy: A Pilot Randomized Controlled Trial (PERQ-UP Pilot) with April 2021 completion date.
Asia Pacific Market Statistics
The Asia Pacific exocrine pancreatic insufficiency treatment market is forecast to increase at a robust pace during the study period. The increasing investments in the advancements of healthcare infrastructure, gut health awareness programs, and initiatives to mitigate cancer cases are augmenting the demand for advanced exocrine pancreatic insufficiency therapeutic solutions. China, India, Japan, and South Korea are offering win-win opportunities for exocrine pancreatic insufficiency drug producers.
In China, rising technological advancements in the field of diagnosis and treatment are set to drive overall exocrine pancreatic insufficiency treatment market growth in the coming years. The rising cases of pancreatic cancer and gastrointestinal disorders are increasing the consumption of exocrine pancreatic insufficiency medications. For instance, the National Center for Biotechnology Information (NCBI) reveals that the prevalence of gastrointestinal discomfort such as constipation is more than 30% in the elderly population.
In India, supportive government policies and initiatives to enhance national health are set to increase the sales of exocrine pancreatic insufficiency drugs in the coming years. For instance, in December 2024, the India Brand Equity Foundation (IBEF) revealed that the government is focusing on improving R&D in the pharma and MedTech sector by investing around USD 82.5 million. The country is also emerging as a global hub for generic drug production, which is leading to the easy availability of cost-effective pancreatic enzyme replacement therapies and drugs.
The exocrine pancreatic insufficiency treatment market is characterized by the presence of industry giants and the emergence of start-ups. The new companies invest heavily in research and development activities to introduce innovative exocrine pancreatic insufficiency treatment options, which aids them to stand out in the crowd. Leading companies are more focused on strategic collaborations with research organizations and other players to expand their product offerings by adding state-of-the-art therapies. This not only increases their market reach but also boosts their revenue shares. Mergers & acquisitions and regional expansion strategies are further aiding them to enhance their market position by adding new products into their product folio and grabbing untapped opportunities in the high-potential economies.
Some of the key players include in exocrine pancreatic insufficiency treatment market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?